Research graph
References from Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Multiple myeloma
10.1038/nrdp.2017.46 · 2017 · External reference
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022 · External reference
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
10.1038/s41375-019-0435-7 · 2019 · External reference
Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
2025 · External reference
Teclistamab: mechanism of action, clinical, and translational science
10.1111/cts.13717 · 2024 · External reference
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
10.1038/leu.2016.388 · 2017 · External reference
Teclistamab, a B-cell maturation antigen×CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
10.1016/s0140-6736(21)01338-6 · 2021 · External reference
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: pooled findings from three clinical cohorts and a retrospective cohort
10.1002/cncr.70237 · 2026 · External reference
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
10.1182/blood.2023023616 · 2024 · External reference
Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study
10.1016/j.clml.2018.06.018 · 2018 · External reference
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
10.1038/s41467-021-21177-5 · 2021 · External reference
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
2023 · External reference
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
10.1038/s41408-025-01314-9 · 2025 · External reference
Unresolved reference
External reference
SurvdigitizeR: an algorithm for automated survival curve digitization
10.1186/s12874-024-02273-8 · 2024 · External reference
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
10.1038/s41408-025-01314-9 · 2025 · External reference
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
2024 · External reference
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
10.1038/s41408-024-01197-2 · 2024 · External reference
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
10.1182/blood.2022015526 · 2023 · External reference
Long-term (≥5-Year) remission and survival after treatment with Ciltacabtagene Autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma
10.1200/jco-25-00760 · 2025 · External reference
Charting the course: sequencing immunotherapy for multiple myeloma
10.1200/edbk_432204 · 2024 · External reference
Teclistamab for relapsed or refractory multiple myeloma: a review of efficacy, safety, resistance mechanisms and future directions
2026 · External reference
Teclistamab plus Daratumumab in relapsed or refractory multiple myeloma
10.1056/nejmoa2514663 · 2026 · External reference
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
10.1186/s12967-025-06543-x · 2025 · External reference
Teclistamab: mechanism of action, clinical, and translational science
10.1111/cts.13717 · 2024 · External reference
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
10.1016/j.ccell.2023.02.008 · 2023 · External reference
Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma
2025 · External reference
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · 2023 · External reference
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
10.3389/fimmu.2024.1433774 · 2024 · External reference
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
10.3324/haematol.2020.266841 · 2023 · External reference
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
10.1097/cco.0000000000000983 · 2023 · External reference
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
2024 · External reference
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: pooled findings from three clinical cohorts and a retrospective cohort
10.1002/cncr.70237 · ExternalCitation · doi-reference
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
10.1016/j.ccell.2023.02.008 · ExternalCitation · doi-reference
Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study
10.1016/j.clml.2018.06.018 · ExternalCitation · doi-reference
Teclistamab, a B-cell maturation antigen×CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
10.1016/s0140-6736(21)01338-6 · ExternalCitation · doi-reference
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
10.1038/leu.2016.388 · ExternalCitation · doi-reference
Multiple myeloma
10.1038/nrdp.2017.46 · ExternalCitation · doi-reference
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
10.1038/s41375-019-0435-7 · ExternalCitation · doi-reference
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
10.1038/s41408-024-01197-2 · ExternalCitation · doi-reference
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
10.1038/s41408-025-01314-9 · ExternalCitation · doi-reference
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
10.1038/s41467-021-21177-5 · ExternalCitation · doi-reference
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · ExternalCitation · doi-reference
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · ExternalCitation · doi-reference
Teclistamab plus Daratumumab in relapsed or refractory multiple myeloma
10.1056/nejmoa2514663 · ExternalCitation · doi-reference
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
10.1097/cco.0000000000000983 · ExternalCitation · doi-reference
Teclistamab: mechanism of action, clinical, and translational science
10.1111/cts.13717 · ExternalCitation · doi-reference
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
10.1182/blood.2022015526 · ExternalCitation · doi-reference
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
10.1182/blood.2023023616 · ExternalCitation · doi-reference
SurvdigitizeR: an algorithm for automated survival curve digitization
10.1186/s12874-024-02273-8 · ExternalCitation · doi-reference
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
10.1186/s12967-025-06543-x · ExternalCitation · doi-reference
Charting the course: sequencing immunotherapy for multiple myeloma
10.1200/edbk_432204 · ExternalCitation · doi-reference
Long-term (≥5-Year) remission and survival after treatment with Ciltacabtagene Autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma
10.1200/jco-25-00760 · ExternalCitation · doi-reference
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
10.3324/haematol.2020.266841 · ExternalCitation · doi-reference
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
10.3389/fimmu.2024.1433774 · ExternalCitation · doi-reference
